Merck claims a needed win for Keytruda with interim OS data in head and neck cancer
Merck has stocked up on data to support moving Keytruda up as a first-line therapy for head and neck squamous cell carcinoma.
An interim analysis of the Keynote-048 study suggested that the checkpoint inhibitor significantly improved overall survival — one of two primary endpoints — in patients whose tumors expressed PD-L1. The dual-primary endpoint of progression-free survival, however, has not been reached.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.